VERICEL CORPORATION Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
VERICEL CORPORATION (VCEL) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $4.70 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-24.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2021-02-24
- VERICEL CORPORATION adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2018 was $4.70M, a 1411.25% increase from fiscal 2017.
- VERICEL CORPORATION adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2017 was $311.00K, a 81.19% decline from fiscal 2016.
- VERICEL CORPORATION adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2016 was $1.65M, a 47.81% decline from fiscal 2015.
- VERICEL CORPORATION adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2015 was $3.17M, a 0.00% change from fiscal 2014.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month as first filed | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 243 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 255 month |
|---|---|---|---|---|
| 2018-12-31 | $4.70M 10-K · filed 2021-02-24 | $4.70K 10-K · filed 2019-02-26 | ||
| 2017-12-31 | $311.00K 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $1.65M 10-K · filed 2019-02-26 | |||
| 2015-12-31 | $3.17M 10-K · filed 2016-03-14 | |||
| 2014-12-31 | $3.17M 10-K · filed 2017-03-13 | $980.00K 10-K · filed 2016-03-14 | ||
| 2010-06-30 | $2.87M 10-K · filed 2013-03-18 | |||
| 2009-06-30 | $2.87M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |